These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 32285172

  • 1. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment.
    Liu Q, Wu H, Li Y, Zhang R, Kleeff J, Zhang X, Cui M, Liu J, Li T, Gao J, Pan B, Wu W, Wang W, Zhou L, Guo J, Dai M, Zhang T, Liao Q, Lu Z, Zhao Y.
    Cancer Immunol Immunother; 2020 Aug; 69(8):1477-1492. PubMed ID: 32285172
    [Abstract] [Full Text] [Related]

  • 2. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G, Zhao J, Qin C, Zhang Z, Lin Y, Su Z.
    Cancer Lett; 2017 Jan 28; 385():65-74. PubMed ID: 27840243
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC, Chafe SC, Brown WS, Saberi S, Swayampakula M, Venkateswaran G, Nemirovsky O, Gillespie JA, Karasinska JM, Kalloger SE, Supuran CT, Schaeffer DF, Bashashati A, Shah SP, Topham JT, Yapp DT, Li J, Renouf DJ, Stanger BZ, Dedhar S.
    Gastroenterology; 2019 Sep 28; 157(3):823-837. PubMed ID: 31078621
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
    Liu Y, Li F, Gao F, Xing L, Qin P, Liang X, Zhang J, Qiao X, Lin L, Zhao Q, Du L.
    Tumour Biol; 2016 Nov 28; 37(11):15283-15291. PubMed ID: 27696296
    [Abstract] [Full Text] [Related]

  • 10. The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells.
    Cioffi M, Trabulo SM, Sanchez-Ripoll Y, Miranda-Lorenzo I, Lonardo E, Dorado J, Reis Vieira C, Ramirez JC, Hidalgo M, Aicher A, Hahn S, Sainz B, Heeschen C.
    Gut; 2015 Dec 28; 64(12):1936-48. PubMed ID: 25887381
    [Abstract] [Full Text] [Related]

  • 11. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
    Zhang Y, Liu L, Fan P, Bauer N, Gladkich J, Ryschich E, Bazhin AV, Giese NA, Strobel O, Hackert T, Hinz U, Gross W, Fortunato F, Herr I.
    Oncotarget; 2015 Apr 30; 6(12):9999-10015. PubMed ID: 25846752
    [Abstract] [Full Text] [Related]

  • 12. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H, Gao W, Li X, Yu L, Luo D, Liu Y, Yu X.
    Pancreatology; 2021 Apr 30; 21(3):589-598. PubMed ID: 33579599
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA, Huang JJ, Starr MD, Treboschi VM, Bernanke AG, Nixon AB, McCall SJ, White RR, Blobe GC.
    Carcinogenesis; 2016 Nov 01; 37(11):1041-1051. PubMed ID: 27604902
    [Abstract] [Full Text] [Related]

  • 15. Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer.
    Liu C, Cheng H, Luo G, Lu Y, Jin K, Guo M, Ni Q, Yu X.
    Int J Oncol; 2017 Aug 01; 51(2):686-694. PubMed ID: 28714519
    [Abstract] [Full Text] [Related]

  • 16. Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts.
    Hermann PC, Trabulo SM, Sainz B, Balic A, Garcia E, Hahn SA, Vandana M, Sahoo SK, Tunici P, Bakker A, Hidalgo M, Heeschen C.
    PLoS One; 2013 Aug 01; 8(6):e66371. PubMed ID: 23825539
    [Abstract] [Full Text] [Related]

  • 17. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
    Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL, Chiao PJ.
    Mol Cancer Ther; 2008 Apr 01; 7(4):829-40. PubMed ID: 18413796
    [Abstract] [Full Text] [Related]

  • 18. Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells.
    Timaner M, Letko-Khait N, Kotsofruk R, Benguigui M, Beyar-Katz O, Rachman-Tzemah C, Raviv Z, Bronshtein T, Machluf M, Shaked Y.
    Cancer Res; 2018 Mar 01; 78(5):1253-1265. PubMed ID: 29301792
    [Abstract] [Full Text] [Related]

  • 19. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Kubo M, Gotoh K, Eguchi H, Kobayashi S, Iwagami Y, Tomimaru Y, Akita H, Asaoka T, Noda T, Takeda Y, Tanemura M, Mori M, Doki Y.
    Ann Surg Oncol; 2020 Feb 01; 27(2):610-619. PubMed ID: 31605325
    [Abstract] [Full Text] [Related]

  • 20. ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression.
    Liu C, Qiang J, Deng Q, Xia J, Deng L, Zhou L, Wang D, He X, Liu Y, Zhao B, Lv J, Yu Z, Lei QY, Shao ZM, Zhang XY, Zhang L, Liu S.
    Cancer Res; 2021 Dec 01; 81(23):5919-5934. PubMed ID: 34580061
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.